ReviewJournal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation2013
Role of HDL dysfunction in end-stage renal disease: a double-edged sword.
Review in Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 78 citations in OpenAlex.
- Hyperphosphatemia and hs-CRP Initiate the Coronary Artery Calcification in Peritoneal Dialysis Patients.BioMed research international · 2017Trial
- Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.Clinical journal of the American Society of Nephrology : CJASN · 2015Trial
- Interrelationships Between Key Cardiovascular Risk Factors, Chronic Kidney Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease.Current cardiology reports · 2026Review
- Article
- Baseline Uric Acid-to-HDL Cholesterol Ratio Predicts Peritoneal Membrane Failure in Peritoneal Dialysis Patients.Journal of clinical medicine · 2026Article
- Serum Amyloid A (SAA) and Its Interaction with High-Density Lipoprotein Cholesterol (HDL-C): A Comprehensive Review.International journal of molecular sciences · 2025Review
- Insulin resistance surrogates predict major adverse cardiovascular events in patients with heart failure with preserved ejection fraction and chronic kidney disease: a retrospective cohort study.Lipids in health and disease · 2025Article
- Association of remnant cholesterol with renal function and its progression in patients with type 2 diabetes related chronic kidney disease.Frontiers in endocrinology · 2024Article
- HDL Function across the Lifespan: From Childhood, to Pregnancy, to Old Age.International journal of molecular sciences · 2023Review
- Modulation of the Cellular microRNA Landscape: Contribution to the Protective Effects of High-Density Lipoproteins (HDL).Biology · 2023Review
- Expanding the Molecular Disturbances of Lipoproteins in Cardiometabolic Diseases: Lessons from Lipidomics.Diagnostics (Basel, Switzerland) · 2023Review
- Non-High-Density Lipoprotein Cholesterol and Progression of Chronic Kidney Disease: Results from the KNOW-CKD Study.Nutrients · 2022Article
- Non-High-Density Lipoprotein Cholesterol and Cardiovascular Outcomes in Chronic Kidney Disease: Results from KNOW-CKD Study.Nutrients · 2022Article
- Blood Plasma Metabolites in Diabetes-Associated Chronic Kidney Disease: A Focus on Lipid Profiles and Cardiovascular Risk.Frontiers in nutrition · 2022Article
- Multi-trajectories of lipid indices with incident cardiovascular disease, heart failure, and all-cause mortality: 23 years follow-up of two US cohort studies.Journal of translational medicine · 2021Article
- Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.Cardiovascular drugs and therapy · 2021Review
- Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?Biomedicines · 2021Review
- Novel Predictors and Risk Score of Treatment Failure in Peritoneal Dialysis-Related Peritonitis.Frontiers in medicine · 2021Article
- There is a U shaped association between non high density lipoprotein cholesterol with overall and cardiovascular mortality in chronic kidney disease stage 3-5.Scientific reports · 2020Article
- The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
End-stage renal disease (ESRD) is associated with a significant propensity for development of atherosclerosis and cardiovascular mortality. The atherogenic diathesis associated with ESRD is driven by inflammation, oxidative stress, and dyslipidemia. Reduced high-density lipoprotein cholesterol (HDL-C) level and high-density lipoprotein (HDL) dysfunction are the hallmarks of ESRD-related dyslipidemia. Clinical and laboratory studies have revealed that ESRD is associated with significantly reduced serum apolipoprotein A-I (ApoA-I) and HDL-C level as well as altered HDL composition. Furthermore, although ESRD is associated with impaired HDL antioxidant and anti-inflammatory properties in most patients, in a small subset, HDL may in fact have a pro-oxidant and proinflammatory effect. Therefore, it is no surprise that serum HDL-C level is not a dependable indicator of cardiovascular disease burden in ESRD, and markers such as HDL function are critical to accurately identifying patients at risk for cardiovascular disease and mortality in ESRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.